⌕
Pfizer · PFE · NYSE
Tenet 50 · Mixed
Compare
$28.86−0.10%At closeTenet 50 · Mixed
$28.86−0.03 (−0.10%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD
$28.860.00 (0.00%)
After hours: Nov 16, 2026, 7:53 PM ET

Pfizer (PFE) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 38% below its peak, net margin 12.5%, and free cash flow (~$9.1B) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($B)▼1.6%
62.6
FY21→FY25CAGR −6.3%/yr
Net income ($B)▼3.1%
7.8
one-off year: see footnoteCAGR −22.8%/yr
Free cash flow ($B)▼7.7%
9.1
FY21→FY25CAGR −25.8%/yr
Diluted EPS▼3.5%
1.36
FY21→FY25CAGR −22.9%/yr
What the receipts whisper · what a headline number hides
Share count
+0.1%

5.7bn → 5.7bn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.

Capex
$2.6B

steady at 4.2% of revenue (−9.6% YoY).

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($B)62.6Revenue−16.1COGS46.5Gross profit−12.1R&D−13.8SG&A14.2Op income−6.4Tax & other7.8Net income

12¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
806040200%sector median net margin ~4%FY21FY25

Over this window: gross 62.1% → 74.3%. Net margin 12.5% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
63,625.062,579.063,627.059,553.0101,175.081,288.0▼1.6%−6.3%
Cost of revenue
16,940.016,067.017,851.024,954.034,344.030,821.0▼10.0%−15.0%
Gross profit
46,685.046,512.045,776.034,599.066,831.050,467.0▲1.6%−2.0%
Research & development
12,555.012,050.010,930.010,873.012,381.013,829.0▲10.2%−3.4%
Selling, general & admin
13,813.013,794.014,730.014,771.013,677.012,703.0▼6.4%+2.1%
Total operating expenses
33,045.032,268.033,365.033,320.031,042.031,034.0▼3.3%+1.0%
Operating incomefeeds ROC rank
13,640.014,244.012,411.01,279.035,789.019,433.0▲14.8%−7.5%
Other income, net
−9,381.0−6,724.0−4,388.0−221.0−1,060.04,878.0——
Pretax income
4,259.07,520.08,023.01,058.034,729.024,311.0▼6.3%−25.4%
Income tax
186.0−266.0−28.0−1,115.03,328.01,852.0▼850.0%—
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
4,072.07,812.08,062.02,158.031,407.022,025.0▼3.1%−22.8%
Per share
Diluted EPSbuyback-sensitive
0.701.361.410.375.473.85▼3.5%−22.9%
Diluted shares (bn)
5.755.715.705.715.735.71▲0.2%+0.0%
Margins
Gross margin63rd pct in Healthcare
73.4%74.3%71.9%58.1%66.1%62.1%▲2.4pp+12.2pp
Operating margin
21.4%22.8%19.5%2.1%35.4%23.9%▲3.3pp−1.1pp
Net margin58th pct in Healthcare
6.4%12.5%12.7%3.6%31.0%27.1%▼0.2pp−14.6pp
† TTM = trailing four quarters through 2026-09-27.FY22 effective tax rate was 10% vs a −0% norm for this window, likely a one-time item; see the filing.FY23 effective tax rate was −105% vs a −0% norm for this window, likely a one-time item; see the filing.
FY07 – FY20 · 14 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 14 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Pfizer's revenue last fiscal year?

Pfizer reported revenue of $62.6B in fiscal 2025, down 1.6% from fiscal 2024.

What was Pfizer's net income?

Pfizer reported net income of $7.8B in fiscal 2025, a net margin of 12.5%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.